Kalvista Pharmaceuticals, INC

Chiesi Group has finalized its acquisition of KalVista Pharmaceuticals for $27.00 per share in an all-cash transaction.

Chiesi Group announced its definitive agreement to acquire KalVista Pharmaceuticals for approximately $1.9 billion in cash, significantly expanding its rare disease portfolio with KalVista's oral HAE therapy.

KalVista Pharmaceuticals reported $49.1 million in EKTERLY net product revenue for the eight-month transition period ended December 31, 2025, driven by rapid US adoption and international expansion.

KalVista Pharmaceuticals announced preliminary Q4 and full-year 2025 revenue for EKTERLY, exceeding expectations with strong patient adoption and international expansion.

KalVista Pharmaceuticals reports strong initial US sales for EKTERLY, expands globally, and secures funding to reach profitability.

KalVista Pharmaceuticals appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer to bolster global EKTERLY launch.

KalVista Pharmaceuticals reports Q1 2026 results, driven by EKTERLY sales, and announces a definitive agreement to be acquired by Chiesi for $27.00 per share.

KalVista Pharmaceuticals reports its first product revenue following the FDA approval and initial commercial launch of EKTERLY for hereditary angioedema, alongside new financing activities.

KalVista Pharmaceuticals reports its first product revenue following the FDA approval and commercial launch of EKTERLY, an oral on-demand therapy for hereditary angioedema.

KalVista Pharmaceuticals' Q3 2025 report details financial results and provides updates on the regulatory submissions for sebetralstat, its oral on-demand therapy for hereditary angioedema (HAE).

KalVista Pharmaceuticals announced its second quarter 2025 results, highlighted by a $100 million upfront payment from a royalty financing agreement and approximately $56 million in net proceeds from equity offerings.

KalVista Pharmaceuticals reports its Q1 2025 results, highlighting progress in its hereditary angioedema (HAE) treatment program, including the acceptance of its New Drug Application (NDA) by the FDA.

KalVista Pharmaceuticals files an amendment to its transition report to include required governance and compensation disclosures ahead of its pending merger.

KalVista Pharmaceuticals reports its first product revenue following FDA approval and global authorizations for EKTERLY, an oral on-demand therapy for HAE, while securing significant financing.

KalVista Pharmaceuticals, Inc. announced the landmark U.S. FDA approval of EKTERLY (sebetralstat), the first and only oral, on-demand therapy for hereditary angioedema (HAE) in patients aged 12 and older, alongside strategic global commercialization partnerships and a significant royalty financing deal.

KalVista Pharmaceuticals has submitted a New Drug Application to the FDA for sebetralstat, a potential first-in-class oral on-demand therapy for hereditary angioedema, with plans for global regulatory submissions.

Director Nancy Stuart reports the disposal of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Director Brian J.G. Pereira reports the cancellation and cash-out of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

KalVista Pharmaceuticals director William Fairey disposed of stock options following the company's acquisition by Chiesi Farmaceutici S.p.A. for $27.00 per share.

KalVista Pharmaceuticals has been acquired by Chiesi Farmaceutici in an all-cash transaction valued at $27.00 per share.

Director Bethany Sensenig reports the cancellation and cash conversion of stock options following the completed merger of KalVista Pharmaceuticals into Chiesi Farmaceutici.

Director Patrick Treanor reports the cancellation of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

KalVista Pharmaceuticals, Inc. announces its upcoming Annual Meeting on October 1, 2025, to vote on director elections, auditor ratification, and executive compensation.

KalVista Pharmaceuticals, Inc. announced its Annual Meeting of Stockholders for October 1, 2025, following recent FDA and UK approvals for EKTERLY (sebetralstat) and new commercialization deals.

KalVista Pharmaceuticals has scheduled its annual stockholder meeting for October 3, 2024, outlining proposals for director elections, auditor ratification, and executive compensation approval.

KalVista Pharmaceuticals will hold its annual stockholders meeting virtually on October 3, 2024, to vote on director elections, auditor ratification, and executive compensation.

Frazier Life Sciences entities and individuals report significant sales of KalVista Pharmaceuticals common stock over a 60-day period ending May 19, 2026.

Frazier Life Sciences funds updated their beneficial ownership in KalVista Pharmaceuticals, Inc. to reflect a merger between two of their investment vehicles.

Frazier Life Sciences funds filed an amended Schedule 13D for KalVista Pharmaceuticals, Inc., clarifying beneficial ownership percentages and attribution.

Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G disclosing that their beneficial ownership in KalVista Pharmaceuticals has fallen below the 5% threshold.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 5.6% of KalVista Pharmaceuticals Inc.'s Class A Common Stock as of March 31, 2026.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, disclosing their beneficial ownership in KalVista Pharmaceuticals, Inc.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, filed an amended Schedule 13G to correct their beneficial ownership of KalVista Pharmaceuticals, Inc. common stock, now reporting a 5.5% stake.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has disclosed a 4.9% beneficial ownership stake in KalVista Pharmaceuticals, Inc.

Millennium Management LLC and affiliated entities have reported a combined 5.9% passive beneficial ownership in KalVista Pharmaceuticals, Inc.